Aratana Gets Rights To Two Compounds For Animal Use

Posted: March 4, 2011, 5:25 p.m., EDT



Published:

Aratana Therapeutics Inc. of Kansas City, Kan., reported today that it has entered into a license agreement with RaQualia Pharma Inc. to develop two compounds from RaQualia’s human clinical development portfolio for companion animal use.

As part of the agreement, Aratana will be granted global rights for development and commercialization of the licensed animal health products. In exchange, the Japanese company will receive upfront payment, development milestones and royalties on global sales.

The first compound is a selective EP-4 antagonist. Aratana reported that the compound has achieved proof of efficacy in human studies and has demonstrated efficacy in animal models for several conditions including, pain, cancer and autoimmune/inflammatory diseases.

The second compound, a selective Ghrelin agonist, has achieved proof of efficacy in human studies and has demonstrated efficacy in animal models for treatment of cachexia and frailty, according to Aratana.

Aratana announced its entry into the animal health industry in early January, which was jump-started by $20 million in Series A financing.


Related story: Aratana Enters Animal Health Industry with $20 Million in Funding

 

 

<Home>

Archive »Read More

NCSU to Host 23nd Annual Dog Olympics Sept. 13

The aim of the event is to celebrate the human-animal bond and raise money for local animal rescue groups.

Michigan State University Co-Hosts 10th Annual Marek’s Disease Symposium

MSU and the USDA’s Avian Disease and Oncology Laboratory recently co-hosted a symposium on Marek’s disease and avian herpesvirus.

Too Many Veterinarians, or a Bubble Market?

How can a scientifically trained profession keep ignoring the facts of too many graduates chasing too few jobs with an ever increasing debt burden?

Add your comment:

Events


Show More...